Ornelas-Arroyo S, Méndez-Sánchez N

Idioma: Inglés.
Referencias bibliográficas: 8
Paginas: 160-162
Archivo PDF: 71.39 Kb.

FRAGMENTO

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Wangs CS, Ko HH, Yoshida EM, Marra CA, Richardson K. I Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 2006; 6: 1586: 1586-99.

2. Castells L, Vargas V, Allende H, Bilbao I, Luis LJ, Margarit C, Esteban R et al. Combined treatment with pegylated interferon (a-2b) and rivabirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005; 43: 53-9.

3. Fukuhara T, Taketomi A, Motomura T, Okano S, Ninomiya A, Abe T, Uchiyama H, et al. Variants in IL28B in liver recipients and donor correlate with response to peg-interferon and rivabirin therapy for recurrent hepatitis C. Gastroenterology 2010; 139: 1577.

4. Wan P, Xia Q, Zhang JJ, Li QG, Xu N, Zhang M, Chen XS, et al. Liver transplantation for hepatocellular carcinoma exceeding the Milan criteria: a single-center experience. J Cancer Res Clin Oncol 2013 Dec 30. [Epub ahead of print].

5. Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis. 2010; 30: 3-16.

6. Aktas S, Karakayali H, Moray G, Haberal N, Bilezikci B, Haberal M. Long-term results of incidental hepatocellular carcinoma after liver transplant. Exp Clin Transplant 2011; 9: 187-90.

7. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 1020-12.

8. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 908-43.